
Sanofi's amlitelimab, dosed every 4 or 12 weeks, was superior to placebo in efficacy and skin clearance, with efficacy increasing throughout the treatment period.
Sanofi's amlitelimab, dosed every 4 or 12 weeks, was superior to placebo in efficacy and skin clearance, with efficacy increasing throughout the treatment period.
Ada Stewart, MD, shares strategies for primary care physicians to reduce patient anxiety and improve comfort during cervical cancer screening exams.
Nor does receiving a diabetes diagnosis guarantee optimal management as just one-fifth of people treated for the disease reached glycemic control in 2023.
Nerandomilast, with a PDUFA date of Q4 2025, leads the potential breakthrough therapies, with inhaled treprostinil and admilparant advancing quickly behind.
Exact Sciences launches Cancerguard, a groundbreaking blood test for early cancer detection, aiming to transform cancer screening and save lives.
Although overall risk was just slightly elevated, study authors recommend alternative imaging methods when appropriate for women of childbearing age.
Your daily dose of the clinical news you may have missed.
Family physician Teresa Lovins, MD, highlights key community mental health resources primary care clinicians should know to support patients in crisis.
Expert discusses when to start screening, available test options, and recommended intervals for women aged 21 to 65 years.
Rocatinlimab offers promise as a novel T-cell rebalancing therapy that targets the OX40 receptor, with maintenance dosing as infrequently as every 8 weeks.
Northeastern states consistently ranked highest on measures including rates of flu vaccination across age groups, number of teens vaccinated against HPV, and older individuals with shingles vaccination.
New data show the LP.8.1-adapted COVID-19 vaccine generates ≥4-fold antibody increases in older and high-risk adults, with no new safety concerns.
Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Your daily dose of the clinical news you may have missed.
Family physician Teresa Lovins, MD, explains how primary care clinicians can determine when to manage depression and when urgent referral is needed.
Michael Crotty, MD, provides practical guidance for on integrating GLP-1 receptor agonists into a comprehensive obesity treatment plan.
Teresa Lovins, MD, describes the PHQ-9, GAD-7, and other brief screeners that help family physicians identify depression, anxiety, ADHD, and bipolar disorder in everyday practice.
Analysis presented at AHA Hypertension 2025 showed fewer than 6% of US adults use salt substitutes, despite their potential to improve BP control.
Your daily dose of the clinical news you may have missed.
This week’s podcast covers psoriasis trial results, intranasal insulin, COVID-19 booster safety, GLP-1 use in diabetes, and RSV vaccine uptake.